Parallelism: considerations for the development, validation and implementation of PK and biomarker ligand-binding...

Area of Science:

• Pharmacology and Biomarker Assay Development
• Analytical Chemistry and Method Validation

Background:

• Parallelism assessment is crucial for validating pharmacokinetic (PK) and biomarker assays.
• Standardized methodologies and acceptance criteria are lacking, leading to variability in assay validation.

Purpose of the Study:

• To discuss fundamental questions regarding the rationale, timing, and methodology of parallelism assessments.
• To review current industry practices for PK and biomarker assays concerning sample selection and pooling.
• To identify outstanding questions and propose a path forward for establishing best practices.

Main Methods:

• Discussion of scientific rationale for different parallelism testing approaches.
• Review of current practices in sample selection and pooling for PK and biomarker assays.
• Identification of key areas requiring further investigation and consensus.

Main Results:

• Current practices for sample selection and pooling in PK and biomarker assays are diverse.
• Significant outstanding questions remain regarding the implementation and acceptance criteria for parallelism testing.
• The need for continued dialogue between industry and regulators is evident.

Conclusions:

• Ongoing collaboration and data sharing are essential for developing standardized best practices in parallelism testing.
• Further research and regulatory discussion are required to address the remaining questions in assay validation.
• Establishing clear guidelines will improve the reliability and interpretability of PK and biomarker data.